On Air Now

Tune in to Listen

99.9 FM Hibbing, MN

Weather

Current Conditions(Hibbing,MN 55746)

More Weather »
62° Feels Like: 62°
Wind: SE 0 mph Past 24 hrs - Precip: 0.01”
Current Radar for Zip

Tonight

Partly Cloudy 53°

Tomorrow

Partly Cloudy 77°

Thurs Night

Isolated Thunderstorms 55°

Alerts

  • 0 Severe Weather Alerts
  • 0 Cancellations

Biogen receives patent until 2028 for Multiple Sclerosis drug Tecfidera

A pedestrian passes the sign outside the headquarters of Biogen Idec Inc. in Cambridge, Massachusetts June 18, 2008. REUTERS/Brian Snyder
A pedestrian passes the sign outside the headquarters of Biogen Idec Inc. in Cambridge, Massachusetts June 18, 2008. REUTERS/Brian Snyder

(Reuters) - Biogen Idec Inc said on Tuesday it has been granted a new patent that will help protect the market exclusivity of its multiple sclerosis drug Tecfidera until 2028.

The new patent covers the dosing regimen for Tecfidera of 480 milligrams a day.

Tecfidera is expected to be approved by the U.S. Food and Drug Administration by the end of March and many analysts expect it to become the leading treatment for multiple sclerosis.

The European Patent Office also determined recently that a patent covering the same dosing regimen for Tecfidera is allowable. Once granted it too would expire in 2028.

(Reporting by Toni Clarke in Washington; Editing by Richard Chang)

Comments